• Contacts
Wednesday, 18 May 2022
  • it Italiano
  • en English
Newsletter
BeBeez
  • .
  • Home
  • RISK CAPITAL
    • Angels & Incubators
    • Equity Crowdfunding
    • Venture Capital
    • Private Equity
    • Club deal
    • Spac
    • Euronext Growth Milan
    • Real Estate
    • Private equity, venture capital and private debt data in the world
    • Private capital in the world
      • Private capital in Europe
      • Private capital in Asia Pacific
      • Private capital in North America
      • Private capital in the rest of the world
    • Real Estate in the world
      • Real estate in Europe
      • Real Estate in Asia Pacific
      • Real Estate in North America
      • Real Estate in the rest of the world
  • CREDIT & DEBT
    • Private Debt
    • Crisis & Relaunch
    • Bad loans and other NPLs
  • ANALYSIS & COLUMNS
    • Insight Views EN
    • Report
    • Beez Peak
    • Comments
    • Data&Analysis
    • Fintech
    • Management
    • Art&Finance
    • GreenBeez
  • TOOLS
    • Sectors & Companies
    • Events
    • BeBeez Academy
  • BEBEEZ PREMIUM
    • BeBeez Private Data
    • BeBeez News Premium
    • Pricing
    • Subscriber Access
  • Login
Abbonati
  • Home
  • RISK CAPITAL
    • Angels & Incubators
    • Equity Crowdfunding
    • Venture Capital
    • Private Equity
    • Club deal
    • Spac
    • Euronext Growth Milan
    • Real Estate
    • Private equity, venture capital and private debt data in the world
    • Private capital in the world
      • Private capital in Europe
      • Private capital in Asia Pacific
      • Private capital in North America
      • Private capital in the rest of the world
    • Real Estate in the world
      • Real estate in Europe
      • Real Estate in Asia Pacific
      • Real Estate in North America
      • Real Estate in the rest of the world
  • CREDIT & DEBT
    • Private Debt
    • Crisis & Relaunch
    • Bad loans and other NPLs
  • ANALYSIS & COLUMNS
    • Insight Views EN
    • Report
    • Beez Peak
    • Comments
    • Data&Analysis
    • Fintech
    • Management
    • Art&Finance
    • GreenBeez
  • TOOLS
    • Sectors & Companies
    • Events
    • BeBeez Academy
  • BEBEEZ PREMIUM
    • BeBeez Private Data
    • BeBeez News Premium
    • Pricing
    • Subscriber Access
  • Login
Abbonati
BeBeez
Home Private Equity

It’s official, Permira strikes control of leading plasma derivatives maker Kedrion and British competitor BPL. Together with ADIA. The Marcucci family and FSI fund to reinvest in the deal. Cdp Equity takes a call option

bebeezbybebeez
21 January 2022
in Companies, Private Equity
A A
Share on FacebookShare on Twitter

Permira, together with the Abu Dhabi Investment Authority (ADIA), the sovereign fund of Abu Dhabi, has officially signed the deal for the acquisition of 65-70% of Kedrion, the leading Italian group in the production of blood products, up to now controlled by the Marcucci family and also owned by Cdp Equity (through FSI Investimenti spa, a joint venture between Cdp Equity at 77.1% and Kuwait Invesmtent Authority at 22.9%) and by the FSI fund. According to BeBeez, Kedrion was valued at around 2 billion euros, considering the 555 million euros of net financial position at the end of September 2021 and an equity value of between 1.3 and 1.5 billion (see here press release by Permira, the one by FSI and the one by Cdp Equity).

For their part, both the Marcucci family and FSI have already undertaken to reinvest upstream of the control chain, while Cdp Equity has reserved a reinvestment option for approximately 5%, alongside the Marcucci’s (17%) and FSI ( 13%). In detail, the acquisition of Kedrion will be made through the newco Kevlar srl, which will acquire the shares of Kedrion from the current shareholders.

It was known that Permira had been in talks for the deal since last December (see here a previous article by BeBeez), but the news is that the transaction has ADIA as a co-investor.

Also as already leaked last December, Permira structured the operation on Kedrion at the same time as the acquisition of Bio Products Laboratory Ltd (BPL), a British company specialized too in plasma derivatives, which had been put up for sale by the Chinese investment group Creat Group after the US government asked that in order to avoid excessive business concentration. BPL specializes in the pharmaceutical sector and Kedrion had studied his dossier last September (see here a previous article by BeBeez). BPL will in turn be acquired by Kevlar and will then be integrated with Kedrion, giving rise to a new company with 1.1 billion euros in revenues and which will employ nearly 4,000 people worldwide.

Permira was advised by Morgan Stanley, EY, Latham & Watkins, Giliberti and Triscornia e Associati. The shareholders of Kedrion were assisted by Lazard, Natixis, Carnelutti and Pedersoli. BofA Securities and Goodwin Procter advised BPL and TII, the sole shareholder of BPL.

Kedrion had closed FY 2020 with a turnover down 13.7% to 697 million euros and an ebitda down 9% to 96 millions, which however was 160.1 millions on an adjusted basis (from 166.1 millions in the 2019), after carrying out investments in the year for 100.5 million, with net financial debt increased to 599 millions (507.1 million net of the impact of IFRS 16) from 442 millions in the previous year (see here here FY 2020 Financial Statements). A trend confirmed in the nine months of 2021, in which Kedrion had a turnover of 415.3 millions (-14% compared to the third quarter of 2020) due to lower plasma sales; an ebitda of 81.9 millions (with profitability up from 13.6% in 2020 to 19.7%); a net financial position of 555.3 millions (excluding the impact of IFRS 16) (see here Interim results for 9 months at 30 September 2021). Speaking of debt, we remind you that last April 2021 Kedrion placed a bond issue of 410 million euro five-year bonds on the Dublin stock exchange at a rate of 3.375%, aimed at refinancing the issues previously made (see here a previous article by BeBeez).

Silvia Oteri

Leading the deal for Permira was  Silvia Oteri,, partner Head of Healthcare, who declared: “We are honored to collaborate with the Marcucci family in this exciting project that brings together two players of the highest level, Kedrion and BPL, in the field of plasma therapies derivatives, a growing sector characterized by a significant yet unanswered demand for therapies. This investment fits perfectly into the Specialty Pharma segment of our strategy: supporting highly specialized companies in attractive and resilient therapeutic areas. Together, the two companies will have a significant portfolio of pharmaceutical products that can help patients with immune or clotting disorders. For our part, we look forward to working with them to build a world-class reality specialized in rare diseases and deeply committed to patients and donors”. Mrs. Oteri was also the director of the creation of Althea (former Pantheon Group), one of the leading European operators in the integrated management services of medical equipment in healthcare facilities, born in 2014 from the merger of Asteral Ltd with Mesa Group Holdings GmbH, both Permira’s portfolio companies at the time. Since then the group has grown successively through acquisitions and in Italy in 2014 it bought and delisted from the Milan Stock Exchange TBS Group, a company that designs and manages clinical engineering services (see here a previous article by BeBeez).

Maurizio Tamagnini

As for FSI, the Kedrion operation was led by the chief investment officer Barnaba Ravanne and the fund’s Pharma team, led by Giacomo Tofani, assisted by the two industrial partners Francesco Granata (a former top manager of Biogen Idec, Schering-Plow Europe and Canada, Pfizer, Pharmacia and Dompè Biotec) and Aldo Magnini (a former top manager Cambrex Profarmaco Milano, the Generic Business Unit of Cambrex USA and Clariant Italy). The pharma, in fact, is one of the sectors in which FSI believes it can play an important role in terms of aggregation and support for the growth of the many Italian SMEs that make it up.

The ceo of FSI sgr, Maurizio Tamagnini, commented: “I met the Marcucci family in 2012, when Kedrion had a turnover of 250 million euros, mainly in Italy. In ten years the company has quadrupled its size, with over 80% overseas and a significant presence in the US This investment testifies to FSI’s role as a partner of courageous family entrepreneurs who open their capital to a patient fund for transformational growth. With this goal, FSI has decided to make a new investment in the new Kedrion-BPL combination to accompany it in the next development phase “.

We recall, in fact, that the FSI fund had entered the capital of Kedrion in October 2019 with 19.59%, investing a total of 150 million euros for the deal, of which 100 millions for the purchase of shares from Sestant Internazionale spa (holding of the Marcucci family) and other 50 millions to underwrite a capital increase. At the same time, FSI Investimenti had subscribed to a further share capital increase of 16.7 million euros to keep its 25.06% stake in the group unchanged (see here a previous article by BeBeez). To date, FSI owns 24.1%, after having further invested in Kedrion last March.

FSI Investimenti had instead joined Kedrion earlier, in May 2012, when Mr. Tamagnini and his team still worked for Fondo Strategico Italiano and also managed FSI Investimenti. The latter had then acquired 18.6% of the group’s capital and resolved to invest up to 150 million euros, of which 75 millions in equity and other 75 millions in convertible bonds, joining the Marcucci family and the Investitori Associati fund in the capital, with the latter who sold back in 2013 its 32.25% stake for 196 millions to the Marcucci’s. Subsequently FSI rounded up its stake, converting part of the bonds, and to date the total investment has been 117 million for 25.1% of the capital.

Following the entry into the capital by FSI Investimenti, Kedrion in the Summer of 2012 bought Rhogam, a division of Johnson & Johnson’s specialized in immunoglobulin, and since then the great growth of the business in the United States has begun. Also in North America, last June 2021 Kedrion announced the purchase of the Canadian Prometic Biotherapeutics Inc. and of the US-based Prometic Bioproduction Inc from Liminal BioSciences Inc., a group specialized in the clinical development of drugs and listed on Nasdaq, in addition to the acquisition from Liminal itself of two plasma collection centers, one located in Amherst (New York, USA) and one in Winnipeg (Manitoba, Canada) with the hiring of the relative staff (see here a previous article by BeBeez).

Today Kedrion boasts an extensive portfolio of 21 pharmaceutical products and over 600 marketing authorizations worldwide. Kedrion operates 6 manufacturing facilities on a global scale and 29 collection centers in the United States. As for BPL, it operates a production plant in Great Britain and a strong presence in the United States, where it has 28 plasma collection centers.

The aim of the combination of the two groups and the entry of new investors is to continue to support the company in organic growth through the internationalization of the existing portfolio and the development of new products and to pursue inorganic growth opportunities to become a diversified and specialized platform in development of treatments for rare diseases.

Paolo Marcucci, president of Kedrion, commented: “We are very happy to partner with Permira, and we are delighted that they share our vision of the enormous global growth potential of this important and dynamic sector. The unified group will not only bring complementary assets. necessary to be a leading global player; it will also allow us to reach more patients who need plasma-derived therapies”.

Tags: Abu Dhabi Investment AuthorityAdiaAltheaCdp EquityFSIFsi InvestimentiItalyKedrionKedrionMarcucciPAprivate equityprivate equity
Sector news and cards : Pharmaceutical & Medical

Iscriviti alle nostre Newsletter

Iscriviti alle newsletter di BeBeez

Iscriviti
Previous Post

Unicredit launches Agorà Finance, the first spv that securitizes and syndicates acquisition finance. Here is how the new structure works

Next Post

Italy’s private equity weekly roundup. News from Biofarma, Alerion Clean Power, Unicredit Leasing, Sestriere, Enipower, Selle Royal and more

Related Posts

Italy’s private equity weekly roundup. News from Althea, ASPI, AC Milan, Isem, Conbipel, Blue Panorama, Italgel, Bologna People Mover and more
Private Equity

Italy’s private equity weekly roundup. News from Althea, ASPI, AC Milan, Isem, Conbipel, Blue Panorama, Italgel, Bologna People Mover and more

13 May 2022
Italy’s chemical group De Nora refinances its debt with a 200 mln euro and 100 mln $ credit facilities
M&A and corporate finance

Italy’s chemical group De Nora refinances its debt with a 200 mln euro and 100 mln $ credit facilities

10 May 2022
Private Equity

Bregal Unternehmerkapital takes control of Italgel, a leading gelatin and collagen maker

9 May 2022
Italy’s private equity weekly roundup. News from Fedrigoni, MBE Worldwide, Coima RES, Be Shaping the Future, Space Capital Club, HIG, Alcedo, FSI, Gruppo Florence, Neo Apotek and more
Private Equity

Italy’s private equity weekly roundup. News from Fedrigoni, MBE Worldwide, Coima RES, Be Shaping the Future, Space Capital Club, HIG, Alcedo, FSI, Gruppo Florence, Neo Apotek and more

6 May 2022
EdiBeez, the publisher of BeBeez and CrowdfundingBuzz, closed in advance its first equity crowdfunding campaign reaching its maximum goal at 400k. Now the company is valued 1.7 mln euro
Equity Crowdfunding

EdiBeez, the publisher of BeBeez and CrowdfundingBuzz, closed in advance its first equity crowdfunding campaign reaching its maximum goal at 400k. Now the company is valued 1.7 mln euro

3 May 2022
Qatar Holding to launch a takeover bid on Coima RES (REIT) in a 361 mln euro max deal. Reason is an easier access to capital markets in order to invest even more in office real estate
Real Estate

Qatar Holding to launch a takeover bid on Coima RES (REIT) in a 361 mln euro max deal. Reason is an easier access to capital markets in order to invest even more in office real estate

2 May 2022
  • Report
  • Events
  • Proposals

Report

Private debt hits a record in Italy in 2021 with volume over 26 mld euro, twice the figure in 2020. The new Report by BeBeez. See here all the tables

Private debt hits a record in Italy in 2021 with volume over 26 mld euro, twice the figure in 2020. The new Report by BeBeez. See here all the tables

14 March 2022
Financing to Italy’s SMEs and startups from fintech platforms reached a total of 8.6 bn euro since the market started in 2014. More than 3.5 bn euro in 2021 only. Here is the new BeBeez’s report

Financing to Italy’s SMEs and startups from fintech platforms reached a total of 8.6 bn euro since the market started in 2014. More than 3.5 bn euro in 2021 only. Here is the new BeBeez’s report

7 March 2022
In 2021 as many as 40 private equity deals in Italy with EV of at least 500 mln euro. All tables in the BeBeez Report 2021

In 2021 as many as 40 private equity deals in Italy with EV of at least 500 mln euro. All tables in the BeBeez Report 2021

7 February 2022
Fintech, startups and scaleups of Italian matrix raised over 900 mln euro in 2021 from 247 mln in 2020. BeBeez Report

Fintech, startups and scaleups of Italian matrix raised over 900 mln euro in 2021 from 247 mln in 2020. BeBeez Report

2 February 2022

Events

Happy April 25th!

Happy April 25th!

24 April 2022
Merry Christmas and a 2021 of rebirth to all our readers!

Merry Christmas and a wish for 2022 to be the real recovery year for everybody

24 December 2021
BeBeez wishes you happy Immaculate Conception holiday and comes back to your desk at full regime on Thursday December 9

BeBeez wishes you happy Immaculate Conception holiday and comes back to your desk at full regime on Thursday December 9

6 December 2021
IPEM is back in Cannes. Let’s meet there on Feb 1-2-3 2022. BeBeez is media partner. Late bird offer until Dec 17th

IPEM is back in Cannes. Let’s meet there on Feb 1-2-3 2022. BeBeez is media partner. Late bird offer until Dec 17th

3 November 2021

Proposals

No Content Available

Co-sponsors

Partners

Tag

Banca Ifis Banco Bpm BeBeez Magazine bilanci bilancio blockchain bond Cdp Equity Coronavirus COVID-19 Credito Fondiario deteriorati Elite Gacs governo Hines hotel Illimity Italia Italy Italy Kryalos Lbo index L Catterton Leanus logistica magazine NB Aurora nexi NPE npl Pir private capital private debt private debt private equity private equity quotazione real estate Roma Round scaleup Utp venture capital venture capital
This site generates cookies, all of which are necessary for it to work properly. Here is our cookie policy page.

Necessary cookies

Cookie Google Analytics

Cookie tecnici

List of cookies - Privacy policy - Cookie policy
x
Cookies?
Bebeez

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

Follow

Risk Capital

  • Angels & Incubators
  • Venture Capital
  • Private Equity
  • Club deal
  • Spac
  • Euronext Growth Milan
  • Real Estate
  • Private equity, venture capital and private debt data in the world
  • Private capital in the world
  • Real Estate in the world

Credit & Debt

  • Private Debt
  • Crisis & Relaunch
  • Bad loans and other NPLs

Analysis & Columns

  • Insight Views EN
  • Report
  • Beez Peak
  • Comments
  • Data & Analysis
  • Fintech
  • Management
  • Art&Finance
  • GreenBeez

Tools

  • Sectors & Companies
  • Events
  • BeBeez Academy

Who we are

  • Who we are
  • What people say about us
  • Contacts

Personal data management

  • Login BeBeez News Premium
  • Subscribe

Information on the site

  • Privacy Policy
  • Terms and conditions of use
  • Cookie Police
  • Site Map

Powered by Olomedia © 2021

  • it Italiano
  • en English
  • Risk Capital
    • Angels&Incubators
    • Equity Crowdfunding
    • Venture Capital
    • Private Equity
    • Club deal
    • Spac
    • Euronext Growth Milan
    • Real Estate
    • Private equity, venture capital and private debt data in the world
    • Private capital in the world
      • Private capital in Europe
      • Private capital in Asia Pacific
      • Private capital in North America
      • Private capital in the rest of the world
    • Real Estate in the world
      • Real estate in Europe
      • Real Estate in Asia Pacific
      • Real Estate in North America
      • Real Estate in the rest of the world
  • Credit & Debt
    • Private Debt
    • Crisis & Relaunch
    • Bad loans and other NPLs
  • Analysis & Columns
    • Insight Views EN
    • Report
    • Beez Peak
    • Comments
    • Data&Analysis
    • Fintech
    • Management
    • Art&Finance
    • GreenBeez
  • Tools
    • Sectors & Companies
    • Events
    • BeBeez Academy
  • Bebeez Premium
    • BeBeez Private Data
    • BeBeez News Premium
    • Pricing
    • Subscriber Access
  • My Account
  • Subscribe

Powered by Olomedia © 2021

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Search...